Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865281 | 0.82 | FFAR1 (0.45) | FFAR1CA2DRD2DRD3HTR6 | |
| SCHEMBL15865039 | 0.82 | FFAR1 (0.45) | FFAR1CA2DRD2DRD3HTR6 | |
| SCHEMBL15865043 | 0.82 | FFAR1 (0.45) | FFAR1CA2DRD2DRD3HTR6 | |
| SCHEMBL567448 | 0.82 | CA2 (0.52) | FFAR1CA2DRD2HTR6MTNR1A | |
| SCHEMBL9375647 | 0.82 | CA2 (0.58) | FFAR1CA2DRD2DRD3CYP2C9 | |
| SCHEMBL24329410 | 0.81 | FFAR1 (0.57) | FFAR1CYP2C9CYP2B6SLCO1B3MTNR1A | |
| SCHEMBL2544576 | 0.80 | CA2 (0.55) | CA2MTNR1A | |
| SCHEMBL7982000 | 0.80 | CA2 (0.55) | CA2MTNR1A | |
| SCHEMBL1545420 | 0.80 | CA2 (0.55) | CA2MTNR1A | |
| SCHEMBL5917859 | 0.80 | FFAR1 (0.49) | FFAR1CA2DRD2DRD3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| WO-2000077000-A9 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | FFAR1 2371/4885CA2 3221/4885DRD2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.